N-acylated hexosamines as nutraceuticals : from shellfish to algae to mammalian bone and joint health

葡萄糖胺（GlcN）被广泛用作治疗关节和骨骼疾病的“非处方”制剂。然而，从临床试验中还不清楚它是否真的有效。GlcN的主要来源是壳聚糖，壳聚糖是从动物界最丰富的聚合物几丁质中提取出来的。所以gln是一种“营养保健品”。我们开发了一系列n -酰化氨基葡萄糖（GlcNAcyls），这是一种化学修饰的营养品，用于兽医和人类应用，主要用于关节炎和骨质疏松症。我们的首选（先导）化合物n -丁基氨基葡萄糖（GlcNBu）在动物模型中已经显示出这些应用的积极作用，GlcN本身没有。我们有初步数据的其他应用包括促进动物生长和体重增加，以及可能提高老年狗的认知和活动能力。GlcNBu似乎没有多少资金

Glucosamine (GlcN) is used extensively as an "over the counter" preparation for joint and bone disorders. However, it is not clear from clinical trials that it actually works. The main source GlcN is chitosan, which is derived from chitin, the most abundant polymer in the animal kingdom. So GlcN is a "nutraceutical". We have developed a series N-acylated glucosamines (GlcNAcyls), which are chemically modified nutriceuticals, for veterinary and human applications, primarily in arthritis and osteoporosis. Our preferred (lead) compound, N-butyryl glucosamine (GlcNBu) has shown positive effects in animal models for these applications, GlcN itself has not. Other applications, for which we have preliminary data, include enhancing animal growth and weight gain and possibly cognition and increased mobility in aged dogs. GlcNBu appears to have very little, if